Aerosolized Bacillus anthracis Infection in New Zealand White Rabbits: Natural History and Intravenous Levofloxacin Treatment

• Published in: Comparative medicine Vol. 60; no. 6; pp. 461 - 468
• Main Authors: Yee, Steven B, Hatkin, Joshua M, Dyer, David N, Orr, Steven A, Pitt, M. Louise M
• Format: Journal Article
• Language: English
• Published: United States American Association for Laboratory Animal Science 01.12.2010
• Subjects: Aerosols; Animals; Anthrax - diagnosis; Anthrax - drug therapy; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - therapeutic use; Antigens, Bacterial - blood; Bacillus anthracis - immunology; Bacteremia - diagnosis; Bacteremia - drug therapy; Biomarkers - blood; Female; Levofloxacin; Male; Ofloxacin - administration & dosage; Ofloxacin - therapeutic use; Rabbit Model; Rabbits; Spores, Bacterial; Time Factors
• ISSN: 1532-0820

The natural history for inhalational Bacillus anthracis (Ames strain) exposure in New Zealand white rabbits was investigated to better identify potential, early biomarkers of anthrax. Twelve SPF Bordetella-free rabbits were exposed to 150 LD50 aerosolized B. anthracis spores, and clinical signs, body temperature, complete blood count, bacteremia, and presence of protective antigen in the blood (that is, antigenemia) were examined. The development of antigenemia and bacteremia coincided and preceded both pyrexia and inversion of the heterophil:lymphocyte ratio, an indicator of infection. Antigenemia was determined within 1 h by electrochemiluminescence immunoassay, compared with the 24-h traditional culture needed for bacteremia determination. Rabbits appeared clinically normal until shortly before succumbing to anthrax approximately 47 h after challenge or approximately 22 h after antigenemia, which suggests a relatively narrow therapeutic window of opportunity. To evaluate the therapeutic rabbit model, B. anthracis-exposed rabbits were treated (after determination of antigenemia and later confirmed to be bacteremic) intravenously with the fluoroquinolone antibiotic levofloxacin for 5 d at a total daily dose of 25 or 12.5 mg/kg, resulting in nearly 90% and 70% survival, respectively, to the study end (28 d after challenge). The peak level for 12.5 mg/kg was equivalent to that observed for a 500-mg daily levofloxacin dose in humans. These results suggest that intravenous levofloxacin is an effective therapeutic against inhalational anthrax. Taken together, our findings indicate that antigenemia is a viable and early biomarker for B. anthracis infection that can be used as a treatment trigger to allow for timely intervention against this highly pathogenic disease.